Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kymera Therapeutics ( (KYMR) ) has issued an announcement.
On February 26, 2026, Kymera Therapeutics entered into a new at-the-market equity offering program with TD Securities (USA) LLC, allowing the company to sell up to $500 million of common stock from time to time on Nasdaq at its discretion, with TD Cowen acting on a best-efforts basis for a commission of up to 3%. The move provides Kymera with flexible access to additional capital while replacing its prior open market sale agreement with Jefferies, which was terminated the same day.
Also on February 26, 2026, Kymera filed a resale prospectus supplement to register the potential resale by certain existing investors of up to 18.8 million common shares and 12.6 million shares underlying pre-funded warrants, without the company issuing new securities or receiving proceeds from any shareholder sales. The filing clarifies that any warrant exercises could generate only minimal cash for Kymera, underscoring that the registration chiefly enhances liquidity options for key shareholders rather than directly funding the company’s operations.
The most recent analyst rating on (KYMR) stock is a Buy with a $140.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.
Spark’s Take on KYMR Stock
According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, declining revenue trend, and deeply negative operating/free cash flow). Offsetting this is a relatively strong earnings-call profile with clear clinical milestones and a sizable cash runway, while technicals are mixed and valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on KYMR stock, click here.
More about Kymera Therapeutics
Kymera Therapeutics, Inc. is a biotechnology company focused on developing targeted protein degradation therapies, leveraging its platform to design small-molecule drugs that harness the body’s own protein disposal system. The company is listed on the Nasdaq Global Market and accesses public equity markets to support its research, development, and commercialization activities.
Average Trading Volume: 992,172
Technical Sentiment Signal: Buy
Current Market Cap: $7.19B
Learn more about KYMR stock on TipRanks’ Stock Analysis page.